Literature DB >> 22029844

The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119.

Virginia M Stone1, Shalinee Dhayal, David M Smith, Carol Lenaghan, Katy J Brocklehurst, Noel G Morgan.   

Abstract

BACKGROUND AND
PURPOSE: β-cells express a range of fatty acid-responsive G protein-coupled receptors, including GPR119, which regulates insulin secretion and is seen as a potential therapeutic target in type 2 diabetes. The long-chain unsaturated fatty acid derivative oleoylethanolamide (OEA) is an endogenous agonist of GPR119 and, under certain conditions, some long-chain unsaturated fatty acids can promote β-cell cytoprotection. It is not known, however, if OEA is cytoprotective in β-cells. The present study has examined this and determined whether GPR119 is involved.
METHODS: Clonal rat insulin-secreting cell lines, BRIN-BD11 or INS-1E, were exposed to fatty acids complexed with BSA. cAMP levels, insulin release and cell viability were measured. Protein expression was studied by Western blotting and receptor expression by RT-PCR. KEY
RESULTS: GPR119 was expressed in both BRIN-BD11 and INS-1E cells and OEA was cytoprotective in these cells. However, cytoprotection was not reproduced by any of a range of selective, synthetic ligands of GPR119. The cytoprotective response to OEA was lost during exposure to inhibitors of fatty acid amide hydrolase (FAAH) suggesting that OEA per se is not the cytoprotective species but that release of free oleate is required. Similar data were obtained with anandamide, which was cytoprotective only under conditions favouring release of free arachidonate. CONCLUSIONS AND IMPLICATIONS: Activation of GPR119 is not required to mediate the cytoprotective actions of OEA in BRIN-BD11 or INS-1E cells. Rather, OEA is internalised and subjected to hydrolysis by FAAH to release free oleate, which then mediates the cytoprotection.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22029844      PMCID: PMC3423238          DOI: 10.1111/j.1476-5381.2011.01755.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  51 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.

Authors:  N H McClenaghan; C R Barnett; E Ah-Sing; Y H Abdel-Wahab; F P O'Harte; T W Yoon; S K Swanston-Flatt; P R Flatt
Journal:  Diabetes       Date:  1996-08       Impact factor: 9.461

3.  Different role of saturated and unsaturated fatty acids in beta-cell apoptosis.

Authors:  Katrin Eitel; Harald Staiger; Mathias D Brendel; Daniel Brandhorst; Reinhard G Bretzel; Hans-Ulrich Häring; Monika Kellerer
Journal:  Biochem Biophys Res Commun       Date:  2002-12-20       Impact factor: 3.575

Review 4.  The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes.

Authors:  C J Hillard; A Jarrahian
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

Review 5.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

6.  Interactions between synthetic vanilloids and the endogenous cannabinoid system.

Authors:  V Di Marzo; T Bisogno; D Melck; R Ross; H Brockie; L Stevenson; R Pertwee; L De Petrocellis
Journal:  FEBS Lett       Date:  1998-10-09       Impact factor: 4.124

7.  Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines.

Authors:  M Asfari; D Janjic; P Meda; G Li; P A Halban; C B Wollheim
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

Review 8.  Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development?

Authors:  C J Fowler; S O P Jacobsson
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002 Feb-Mar       Impact factor: 4.006

9.  Evidence against the presence of an anandamide transporter.

Authors:  Sherrye T Glaser; Nada A Abumrad; Folayan Fatade; Martin Kaczocha; Keith M Studholme; Dale G Deutsch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-24       Impact factor: 11.205

10.  Mono-unsaturated fatty acids protect against beta-cell apoptosis induced by saturated fatty acids, serum withdrawal or cytokine exposure.

Authors:  Hannah J Welters; Moh Tadayyon; John H B Scarpello; Stephen A Smith; Noel G Morgan
Journal:  FEBS Lett       Date:  2004-02-27       Impact factor: 4.124

View more
  5 in total

1.  Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.

Authors:  A M McKillop; B M Moran; Y H A Abdel-Wahab; P R Flatt
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  High-throughput screening and bioinformatic analysis to ascertain compounds that prevent saturated fatty acid-induced β-cell apoptosis.

Authors:  Seung-Hee Lee; Daniel Cunha; Carlo Piermarocchi; Giovanni Paternostro; Anthony Pinkerton; Laurence Ladriere; Piero Marchetti; Decio L Eizirik; Miriam Cnop; Fred Levine
Journal:  Biochem Pharmacol       Date:  2017-05-15       Impact factor: 6.100

3.  Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity.

Authors:  Jonnell C Small; Aidan Joblin-Mills; Kaycee Carbone; Maria Kost-Alimova; Kumiko Ayukawa; Carol Khodier; Vlado Dancik; Paul A Clemons; Andrew B Munkacsi; Bridget K Wagner
Journal:  ACS Chem Biol       Date:  2022-04-19       Impact factor: 4.634

4.  Oleoylethanolamide Supplementation Reduces Inflammation and Oxidative Stress in Obese People: A Clinical Trial.

Authors:  Laleh Payahoo; Yaser Khajebishak; Mohammad Asghari Jafarabadi; Alireza Ostadrahimi
Journal:  Adv Pharm Bull       Date:  2018-08-29

5.  DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice.

Authors:  Youjin Kim; Si Woo Lee; Hyejin Wang; Ryeong-Hyeon Kim; Hyun Ki Park; Hangkyu Lee; Eun Seok Kang
Journal:  Diabetes Metab J       Date:  2022-01-21       Impact factor: 5.376

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.